SCHEMBL2922360

SCHEMBL2922360

O=C(O)c1c[nH]c(=O)c2cc(S(=O)(=O)O)ccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 7/20 0.56
▸ HSD17B10 Q99714 6/20 0.49
▸ HPGD P15428 5/20 0.49
▸ ALDH1A1 P00352 3/20 0.49
▸ GAA P10253 2/20 0.44
▸ MAPT P10636 2/20 0.44
▸ CYP2C19 P33261 2/20 0.44
▸ PARP1 P09874 1/20 0.43
▸ PTPN11 Q06124 1/20 0.41
▸ DYRK1A Q13627 1/20 0.40
▸ MEN1 O00255 4/20 0.40
▸ KMT2A Q03164 4/20 0.40
▸ POLB P06746 3/20 0.40
▸ USP2 O75604 1/20 0.40
▸ PTPN7 P35236 1/20 0.40
▸ CYP2C9 P11712 2/20 0.39
▸ S1PR3 Q99500 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ CSNK2A2 P19784 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2920920 0.86 KDM4E (0.54) KDM4EHSD17B10HPGDALDH1A1GAA
SCHEMBL2922964 0.86 KDM4E (0.54) KDM4EHSD17B10HPGDGAAMAPT
SCHEMBL2916302 0.86 KDM4E (0.54) KDM4EHSD17B10HPGDALDH1A1GAA
SCHEMBL2923292 0.82 KDM4E (0.50) KDM4EHSD17B10HPGDGAAMAPT
SCHEMBL2913348 0.82 KDM4E (0.50) KDM4EHSD17B10HPGDALDH1A1GAA
SCHEMBL3282728 0.82 GAA (0.58) KDM4EHSD17B10HPGDGAAMAPT
SCHEMBL2916325 0.80 KDM4E (0.54) KDM4EHSD17B10HPGDGAAMAPT
SCHEMBL11336339 0.80 ALDH1A1 (0.58) KDM4EHSD17B10HPGDALDH1A1CYP2C19
SCHEMBL31030047 0.80 ALDH1A1 (0.58) KDM4EHSD17B10HPGDALDH1A1CYP2C19
SCHEMBL3282678 0.78 PARG (0.50) KDM4EHSD17B10ALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1478624-B1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2010-09-08 — — EP disclosed
US-7709500-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-05-04 — — US disclosed
CN-100564358-C The method of a kind of preparation 4-(3, the 4-dichlorophenoxy) piperidines ASTRAZENECA AB (SE) 2009-12-02 — — CN disclosed
CN-100352807-C substituted piperidine compounds ASTRAZENECA AB (SE) 2007-12-05 — — CN disclosed
CN-1907968-A Method for making 4-(3,4-dichlorophenoxy)piperidine ASTRAZENECA AB (SE) 2007-02-07 — — CN disclosed
CN-1633414-A Compound (I) ASTRAZENECA AB (SE) 2005-06-29 — — CN disclosed
US-20050107428-A1 Chemical compounds ASTRAZENECA AB (SE) 2005-05-19 — — US disclosed
EP-1478624-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2004-11-24 — — EP disclosed
WO-2003068743-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2003-08-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107428-A1 Chemical compounds CCR10, CCR3, CXCR5 KDM4E 1685/4885HSD17B10 381/4885HPGD 1414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback